Alector to Participate at the Cowen 42nd Annual Health Care Conference
Alector, a clinical-stage biotechnology company, will participate in a panel discussion at the Cowen Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alector, a clinical-stage biotechnology company, will participate in a panel discussion at the Cowen Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET. The event will be available via a live webcast on Alector's 'Events & Presentations' page in the Investors section of their website. After the event, a replay will be accessible for 30 days. Alector focuses on immuno-neurology therapies targeting neurodegenerative diseases by repairing immune dysfunction and aims to develop treatments for conditions like frontotemporal dementia and Alzheimer’s disease.
Details
News Market Reaction – ALEC
The recorded move for ALEC in the trading session of this news was -1.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced management will participate in a panel discussion at the Cowen Annual Health Care Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.
A live webcast of the panel will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Contacts:
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Eric Kasper/Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.